Analysis of ligand–receptor interactions for the immune checkpoint genes demonstrate that the major PD-L1 signal was provided by tumor cells of the basal/squamous subtype, suggesting alterations in tumor cells and TME by tipifarnib could be reversed by PD-1/PD-L1 ICIs. The gene discussed is CD274; the disease is neoplasm.